In consultation: Guidance and quality standards
Showing 1 to 11 of 11
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] | Draft guidance | Technology appraisal guidance | |
| Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Draft guidance | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Guidance on the use of electroconvulsive therapy | Review proposal consultation | Technology appraisal guidance | |
| Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459] | Draft guidance | Technology appraisal guidance | |
| Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Baxdrostat for treating uncontrolled or resistant hypertension [ID6623] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |